

# Vasalgel Update

## Dear Friend,

As we near the end of 2023, it's a good time to update you on Vasalgel male contraceptive. In case you missed previous newsletters, in 2022 we decided to partner with NEXT Life Sciences to bring Vasalgel to market. Progress on the product has really taken off!

L.R. Fox, CEO of NEXT Life Sciences, is passionate about making sure that everyone can choose when and whether to have a child. In a short time, he has brought together:

- a team with extensive expertise in the development of new medical products;
- a world-renowned medical advisory board; and
- resources to rapidly develop the male contraceptive and prepare for the first clinical trials.



## Plan A

The new product is called "Plan A" – the first long-acting, reversible male contraceptive based on Vasalgel technology.

For more details on Plan A, take a look at some of the links below. And to stay in the loop, be sure to sign up for the Plan A [mailing list](#) and follow Plan A on [social media](#)!

If you're interested in investing opportunities, a crowdfunding effort for accredited investors is underway. If interested, please register at [AngelList](#) to learn more. And accredited investors interested in investing directly with NEXT Life Sciences should contact them at [Plan A](#).

[Subscribe](#)[Past Issues](#)[Translate](#) ▼[RSS](#) 📡

## Thank you!

From all of us at the Parsemus Foundation, we wish you a joyful 2024!

Linda Brent, PhD

Executive Director, Parsemus Foundation



## More information

News about Plan A:

- [What Should the Future Look Like?](#)
- [New Horizons in Birth Control for Men](#)
- [This World Vasectomy Day, Let's Look to Vasectomies and Beyond](#)
- [TikTok video](#)
- [A Birth Control Revolution: New Options for Men on the Horizon](#)
- [Congressional Briefing: The Latest Insights and Opportunities for Improving Family Planning Options for Maternal Wellbeing](#)
- [NEXT Life Sciences Is Making Effective, Reversible Male Contraceptive a Reality](#)
- [Plan A: Viable male birth control options could be on the horizon](#)

Also, two new reviews on the status of new contraceptive development:

- [Male contraception: narrative review of ongoing research](#)
- [Non-hormonal contraception](#)

*Copyright © 2023 Parsemus Foundation, All rights reserved.*

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).